



**Commercial/Healthcare Exchange Quantity Limit Criteria**  
*Effective: September 2<sup>nd</sup>, 2020*

**Quantity Limit Name:** Rukobia

**Products Affected:** Rukobia (fostemsavir) extended-release oral tablets

**Type of Quantity Limit:**

- FDA maximum
- Usual Daily Frequency
- Split fill
- Other (Please specify): \_\_\_\_\_

**Limits to be applied:**

Coverage will be provided only up to the limits specified below.

Rukobia 600mg extended-release oral tablets

Quantity Limit: 60 tablets per 30 days

**References:**

1. Rukobia™ extended-release tablets [prescribing information]. Research Triangle Park, NC: ViiV/GlaxoSmithKline; July 2020.

**Policy Revision history**

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	9/2/2020

Last Res. September 2020

This document is confidential and proprietary to ConnectiCare, Inc. Unauthorized use and distribution are prohibited.